Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 4-week, Open-Label Extension Study of ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) Treatment for Opioid-Tolerant Children and Adolescents With Breakthrough Pain

NCT00236093 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT00236093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00236093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 4-week, Open-Label Extension Study of ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) Treatment for Opioid-Tolerant Children and Adolescents With Breakthrough Pain
Lead sponsor
Cephalon
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2006
Completion date
Not reported
Enrollment
Not reported
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, pain, severe burns, sickle cell anemia